Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion

Cancer Research

Volumn 74, Issue 23, 2014, Pages 7003-7013

  Kalra, Ashish V ^a   Kim, Jaeyeon ^a   Klinz, Stephan G ^a   Paz, Nancy ^a   Cain, Jason ^a   Drummond, Daryl C ^a   Nielsen, Ulrik B ^a   Fitzgerald, Jonathan B ^a  

^a MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; FIRTECAN; IRINOTECAN; LIPOSOME; NANOLIPOSOME; NANOMATERIAL; PRODRUG; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DEPOSITION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG TRANSFORMATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOSOMAL DELIVERY; LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHARMACODYNAMICS; PLASMA CLEARANCE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA; COLONIC NEOPLASMS; DRUG SCREENING; HT 29 CELL LINE; MOUSE; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA; COLONIC NEOPLASMS; FEMALE; HT29 CELLS; HUMANS; LIPOSOMES; MICE; MICE, INBRED NOD; MICE, SCID; PRODRUGS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918536630     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0572     Document Type: Article

References (35)

1. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691-743.
2. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010;21:797-802.
3. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Liposomebased approaches to overcome anticancer drug resistance. Drug Resist Updat 2003;6:271-9.
4. Petitprez A, Poindessous V, Ouaret D, Regairaz M, Bastian G, Guérin E, et al. Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status. Int J Oncol 2013;42:1644-53.
5. Papahadjopoulos D, Gabizon A. Targeting of liposomes to tumor cells in vivo. Ann N Y Acad Sci 1987;507:64-74.
6. Marsh S, Hoskins JM. Irinotecan pharmacogenomics. Pharmacogenomics 2010;11:1003-10.
7. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
8. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009;109:2894-902.
9. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 2006;66:3271-7.
10. Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 2013;02:1-7.
11. El-Kareh AW, Secomb TW. Theoretical models for drug delivery to solid tumors. Crit Rev Biomed Eng 1997;25:503-71.
12. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13:1777-85.
13. Harashima H, Tsuchihashi M, Iida S, Doi H, Kiwada H. Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes. Adv Drug Deliv Rev 1999;40:39-61.
14. Hendriks BS, Reynolds JG, Klinz SG, Geretti E, Lee H, Leonard SC, et al. Multiscale kinetic modeling of liposomal doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors. CPT Pharmacometrics Syst Pharmacol 2012;1:e15.
15. Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 2006;20:163-75.
16. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989;49:6365-8.
17. Morton CL, Iacono L, Hyatt JL, Taylor KR, Cheshire PJ, Houghton PJ, et al. Activation and antitumor activity of CPT-11 in plasma esterasedeficient mice. Cancer Chemother Pharmacol 2005;56:629-36.
18. Azrak RG, Cao S, Slocum HK, Töth K, Durrani FA, Yin M, et al. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 2004;10:1121-9.
19. Raue A, Kreutz C, Maiwald T, Bachmann J, Schilling M, Klingmüller U, et al. Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood. Bioinformatics 2009;25:1923-9.
20. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
21. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y. Topoisomerase Irelated parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995;55:2116-21.
22. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010;7:653-64.
23. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
24. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, et al. Stromal biology and therapy in pancreatic cancer. Gut 2011;60:861-8.
25. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997;70:335-40.
26. Pavillard V, Agostini C, Richard S, Charasson V, Montaudon D, Robert J. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol 2002;49:329-35.
27. Pavillard V, Charasson V, Laroche-Clary A, Soubeyran I, Robert J. Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study. Anticancer Res 2004;24:579-85.
28. Danks MK, Morton CL, Pawlik CA, Potter PM. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res 1998;58:20-2.
29. Kojima A, Hackett NR, Ohwada A, Crystal RG. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest 1998;101:1789-96.
30. Xu G, Zhang W, Ma MK, McLeod HL. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 2002;8:2605-11.
31. Igarashi M, Osuga J, Uozaki H, Sekiya M, Nagashima S, Takahashi M, et al. The critical role of neutral cholesterol ester hydrolase 1 in cholesterol removal from human macrophages. Circ Res 2010;107:1387-95.
32. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008;26:2690-8.
33. Alagoz M, Gilbert DC, El-Khamisy S, Chalmers AJ. DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Curr Med Chem 2012;19:3874-85.
34. Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer 2012;106:18-24.
35. Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990;50:1715-20.